Liminatus Pharma, Inc. (LIMNW) company profile
Close on Oct 30, 2026Market cap $189.39MP/E –Yield –
About Liminatus Pharma
Biological Products, (No Diagnostic Substances), SIC 2836
Liminatus Pharma, Inc. is a preclinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies. Its principal product candidate is IBA101, a next-generation humanized anti-CD47 monoclonal antibody designed to act as an immune checkpoint inhibitor. The therapy works by blocking the CD47 signal that allows malignant cells to evade immune detection, thereby promoting tumor uptake by macrophages while avoiding the destruction of red blood cells and platelets. The company intends to direct its initial treatments toward patients diagnosed with advanced solid tumors, including non-small cell lung cancer.
The company operates as a clinical development-stage enterprise preparing regulatory filings for human clinical evaluations. Its development plans include conducting a global Phase 1 trial focused on lung cancer patients in South Korea. Liminatus Pharma maintains its corporate executive offices in Cerritos, California.
Summary of the business section of Liminatus Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Liminatus Pharma, Inc.
- Founded
- 2018
- Headquarters
- Cerritos, CA
- Address
- 12611 Hiddencreek Way, Unit C 90703
- Phone
- (213) 273-5453
- Employees
- 1, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, Whippany, New Jersey
Stock & identifiers
- Ticker
- LIMNW
- Other tickers
- LIMN
- Exchange
- Nasdaq
- IPO date
- May 2, 2025
- Shares outstanding
- 67M, Aug 14, 2026
- Public float
- $221.00M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-50 reverse, Aug 21, 2026; 175000-for-1, Oct 6, 2025
- SEC CIK
- 1971387
- CUSIP
- 53271X116
- ISIN
- US53271X1164
- FIGI
- BBG01HX018N0
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Chris Kim | Chief Executive Officer, Director | 6,169,406 |
| Beom Kyu Choi | Chief Technology Officer | – |
| Scott Dam | Chief Financial Officer | – |
| Sang-Jin Lee | Head of Research & Development | – |
| Byong Chul Yoo | Chief Science Officer | – |
| II Philip Wayne Lemons | Director | – |
| Richard JaiHwan Baek | Director | – |
| Eun Sook Lee | Director | – |
| Nicholas Fernandez | Director | – |
| Ji Yeon Baek | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Total | vs. prior year |
|---|---|---|---|
| Chris Kim Chief Executive Officer | $183.33K | $183.33K | +27% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Corporate history
Events identified from SEC filings